QRON - Qrons Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.4600
0.0000 (0.00%)
At close: 2:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.4600
Open1.9000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4600 - 1.4600
52 Week Range0.7200 - 3.9000
Volume1,050
Avg. Volume194
Market Cap18.932M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire24 days ago

    Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities

    Dr. Bonfiglio’s primary responsibility will be to oversee all investigational new drug (“IND”) activities in the United States in coordination with Qrons’ Israeli-based scientific team. The hiring of Dr. Bonfiglio represents another step in the Company’s strategy to strengthen its U.S. operations as it continues its regulatory approval efforts for its IND.

  • GlobeNewswire2 months ago

    Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations

    New York, NY, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries, announced today the appointment of Dr. Motti Ratmansky, a member of Qrons’ Scientific Advisory Board as Special Advisor to the Company for IND & Clinical Trials.  Remaining on the Scientific Advisory Board, Dr. Ratmansky will take a more active role as Senior Advisor to assist the Company in preparing for its IND (“Investigational New Drug”) filing. This represents the Company’s further steps to enhance its operation for its IND and clinical trial enabling process, including the possible addition of US-based individuals.

  • GlobeNewswire3 months ago

    Qrons Announces Filing of PCT Patent -- Techniques for Promoting Neuronal Recovery

    NEW YORK, NY, April 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries, announced today that its PCT (“Patent Cooperation Treaty”) patent application, “Techniques for Promoting Neuronal Recovery”, relating to the treatment of traumatic injury to the central nervous system, such as TBI was filed on April 7, 2019 (Application No. PCT/IB2019/052850).

  • ACCESSWIRE5 months ago

    Qrons Retains Investment Banking Firm Network1 Financial Securities Inc.

    MIAMI, FL / ACCESSWIRE / February 21, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel- based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), both concussions and penetrating injuries , announced today that it has retained investment banking firm Network1 Securities Inc. ("Network1") as its Capital Markets Advisory and Investment Banking firm. Network1 will act as Qrons' Advisor and Banker in connection with the overall management of its recent OTC listing, including the functions of capital raising, investor management, and guidance and support for a possible uplisting to a major exchange when appropriate.

  • ACCESSWIRE6 months ago

    Qrons Completes Successful In-Vivo Experiment with its QS100 Candidate Product for Treating Penetrating Brain Injuries in an Animal Model

    Preparing for animal In-vivo efficacy experiments with its QS200™ Candidate Product for treating Concussions and other Diffused Axonal Injuries. MIAMI, FL / ACCESSWIRE / January 30, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons "or the "Company"), a preclinical biotechnology company developing advanced stem cell-synthetic hydrogel based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it had reached a milestone with the development of its two candidate products, QS100™ for treating penetrating brain injuries and QS200™, for treating concussions and other diffused axonal Injuries. Both QS100™ and QS200™ integrate proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material.

  • ACCESSWIRE8 months ago

    Qrons Enters into Placenta Sourcing Agreement under the Declaration of Helsinki

    MIAMI, FL / ACCESSWIRE / November 7, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it has entered into an Agreement with Meir Hospital in Israel to obtain a reliable source of human placentas. This will allow Qrons to carry out development of its proprietary epigenetic modification system to induce neuronal differentiation of mesenchymal stem cells ("MSCs").